Novartis' Jakavi will be available to patients in Scotland with the bone marrow cancer myelofibrosis after a positive verdict from the Scottish Medicines Consortium (SMC). Jakavi (ruxolitinib) is ...

Novartis' blood cancer drug Jakavi has been cleared in the EU to treat polycythaemia vera (PV), a new indication that could catapult the drug to blockbuster status. Jakavi is already approved in ...